-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43

Benzinga·06/30/2026 12:47:57
Listen to the news
Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $32 to $43.